Bär FW, Vermeer F, Michels R, Boland J, Meyer J, Hopkins G, Barth H, Grünzler WA
University Hospital Maastricht, Department of Cardiology, P.O. Box 5800, 6202 AZ Maastricht, The Netherlands.
J Thromb Thrombolysis. 1995;2(3):195-204. doi: 10.1007/BF01062710.
Saruplase is an unglucosylated single-chain recombinant urokinase-type plasminogen activator. Dose finding studies in patients with acute myocardial infarction indicated that a dose of 80 mg of saruplase, given as a bolus of 20 mg and iv infusion of 60 mg in one hour, led to excellent patency figures.Saruplase is most effective when combined with a bolus of 5000 IU heparin followed by an iv heparin infusion for at least 24 hours.When saruplase is compared to other thrombolytic agents (streptokinase, alteplase, urokinase), it becomes apparent that its profile is excellent. Early patency rates are at least comparable to alteplase. Further reocclusion rates of saruplase after one day are lower than those of streptokinase and alteplase. Patency rates 24-72 hours after start of medication are comparable between saruplase and urokinase.The large database in over 6000 patients shows that saruplase, in comparison to the other thrombolytic agents, is safe. Its bleeding complication rate is significantly lower than streptokinase, and a trend to lower in-hospital mortality is observed when compared to urokinase.Summarizing, when comparing to the presently available thrombolytic agents, saruplase is a fast acting, effective and safe thrombolytic agent.
沙芦普酶是一种未糖基化的单链重组尿激酶型纤溶酶原激活剂。对急性心肌梗死患者进行的剂量探索研究表明，80毫克沙芦普酶的剂量，以20毫克静脉推注并在1小时内静脉输注60毫克的方式给药，可产生极佳的血管再通率。沙芦普酶与5000国际单位肝素静脉推注联合，随后至少24小时静脉输注肝素时效果最佳。当将沙芦普酶与其他溶栓剂（链激酶、阿替普酶、尿激酶）进行比较时，很明显其表现出色。早期血管再通率至少与阿替普酶相当。沙芦普酶一天后的再闭塞率低于链激酶和阿替普酶。用药开始后24至72小时的血管再通率在沙芦普酶和尿激酶之间相当。超过6000名患者的大型数据库表明，与其他溶栓剂相比，沙芦普酶是安全的。其出血并发症发生率显著低于链激酶，与尿激酶相比，住院死亡率有降低趋势。总之，与目前可用的溶栓剂相比，沙芦普酶是一种起效快、有效且安全的溶栓剂。
